Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiorenal Syndrome and Depressive Symptoms: Exploring the Mood-Kidney Link With Heart Failure Risk in a Post-hoc Analysis of SPRINT.

Kidney medicine·2026
Same author

Determining the individualized probability of myocardial recovery: The multicenter RecoverHeart calculator.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Implementation of Embedded Specialty Palliative Care in an Advanced Heart Failure and Transplant Clinic.

The American journal of cardiology·2026
Same author

Bucking Conventional Wisdom: The Experience of Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy.

JACC. Heart failure·2026
Same author

Factors associated with native heart survival and intermediate-term outcomes in acute myocardial infarction-related cardiogenic shock.

European heart journal open·2026
Same author

The Effect of Vericiguat on Endothelial Function in Patients With Heart Failure With Reduced Ejection Fraction: A Pilot Randomized Study.

The American journal of cardiology·2026
Same journal

The authors reply.

Critical care medicine·2026
Same journal

Attracting Emergency Medicine Graduates to Surgical Critical Care Training Programs.

Critical care medicine·2026
Same journal

The authors reply.

Critical care medicine·2026
Same journal

Beyond a Snapshot: Tracking Family Prognostic Expectations in the ICU.

Critical care medicine·2026
Same journal

The authors reply.

Critical care medicine·2026
Same journal

Plasma Levels of Soluble ST2 Reflect Extrapulmonary Organ Dysfunction and Predict Outcomes in Acute Respiratory Failure: Beware of Potential Confounders.

Critical care medicine·2026
See all related articles

Related Experiment Video

Updated: Jul 8, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Devices in acute heart failure.

Parag Kale1, James C Fang

  • 1Division of Cardiovascular Medicine, University Hospitals-Case Medical Center, Case Western Reserve University, Cleveland, OH, USA.

Critical Care Medicine
|February 15, 2008
PubMed
Summary
This summary is machine-generated.

Mechanical devices offer new nonpharmacologic strategies for acute heart failure management. These advanced technologies supplement traditional drug treatments, addressing critical issues like circulatory and respiratory failure in cardiac patients.

More Related Videos

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

Related Experiment Videos

Last Updated: Jul 8, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

Area of Science:

  • Cardiology
  • Medical Technology
  • Heart Failure Management

Background:

  • Traditional management of acutely decompensated heart failure primarily relies on pharmacologic agents.
  • Technological advancements have introduced mechanical devices as supplementary treatment options.

Purpose of the Study:

  • To explore the role of emerging mechanical devices in managing acute heart failure.
  • To highlight how these devices address specific patient needs beyond pharmacologic therapy.

Main Methods:

  • Review of current and emerging mechanical circulatory support and respiratory support devices.
  • Analysis of device applications targeting circulatory failure, volume overload, renal insufficiency, and respiratory failure.

Main Results:

  • Mechanical devices provide diverse nonpharmacologic interventions for acute heart failure.
  • These technologies address complex patient conditions, including circulatory, renal, and respiratory compromise.

Conclusions:

  • Mechanical devices are increasingly important in the comprehensive management of acute heart failure.
  • Future innovations in cardiac technology may establish these devices as a cornerstone of treatment strategies.